Trial · NCT07161778
A Trial of Triamcinolone With a GnRH Analog for Castration Resistant Prostate Cancer
NCT07161778, Phase 2, Completed, Barts & The London NHS Trust
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Trial of Triamcinolone With a GnRH Analog for Castration Resistant Prostate Cancer. Trials, record NCT07161778. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07161778
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Trial of Triamcinolone With a GnRH Analog for Castration Resistant Prostate Cancer
- NCT number
- NCT07161778
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 55 participants, actual
- Lead sponsor
- Barts & The London NHS Trust
- Conditions
- Castration Resistant Prostate Cancer
- Interventions
- Triamcinolone acetonide IM injection
- First posted
- 2025-09-09
- Last updated
- 2025-09-09
- Other registries' IDs
- eudract:2010-022010-32
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression free survival in patients with CRPC | 6 months | To examine whether triamcinolone (IM injection) offers an increased progression free survival (PFS) in patients with confirmed CRPC. |
| Secondary | Time to PSA progression according to PCWG2 | Measured at the beginning of every treatment cycle (Time to PSA progression from baseline - 6 month) | Serum collected will be tested for PSA progression |
| Secondary | Circulating Tumour Cells response in patients after 28 days of treatment | Circulating Tumour Cells results at baseline and taken 28 days post baseline will be compared | Comparing CTC at baseline to 28 days |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers12
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07161778
GET https://conductscience.org/api/trials/v1/NCT07161778/registered